Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 7/20 | 0.32 |
| ▸ | MMP2 | P08253 | 6/20 | 0.32 |
| ▸ | MMP1 | P03956 | 5/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88565 | 1.00 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL3458098 | 1.00 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| Hydrochloric Acid SCHEMBL76316 | 0.97 | CA2 (0.36) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| Hydrochloric Acid SCHEMBL17392837 | 0.97 | CA2 (0.36) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL2089233 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTPTGS1TP53TSHR | |
| SCHEMBL2089231 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTPTGS1TP53TSHR | |
| SCHEMBL162227 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL18095144 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL18095145 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL28479550 | 0.78 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1272114-A | Phenethylamine derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2000-11-01 | — | — | CN | claimed |
| US-20250369029-A1 | METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250129398-A1 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-24 | — | — | US | disclosed |
| EP-4520829-A1 | METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023219156-A1 | METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE | 中外製薬株式会社 | 2023-11-16 | — | — | WO | disclosed |
| EP-3339315-B1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | RETROTOPE INC (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023127752-A1 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | 中外製薬株式会社 | 2023-07-06 | — | — | WO | disclosed |
| EP-4206322-A2 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023089542-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2023-05-25 | — | — | WO | disclosed |
| US-5476841-A | Inhibitors of herpes viral ribonucleotide reductase | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1995-12-19 | — | — | US | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
| EP-0411334-B1 | Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-02-22 | — | — | EP | disclosed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | disclosed |
| EP-0618226-A1 | Inhibitors of herpes viral ribonculeotide reductase | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994020528-A1 | INHIBITORS OF HERPES VIRAL RIBONUCLEOTIDE REDUCTASE | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-09-15 | — | — | WO | disclosed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| EP-0493770-A2 | Antiherpes compositions | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | disclosed |
| EP-0411334-A1 | Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | CA2 814/4885ALDH1A1 3285/4885MAPT 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.